- Home
- INAB vs IOBT Comparison
INAB vs IOBT Comparison
Compare INAB & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INAB | IOBT |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 12.7M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INAB | IOBT |
|---|---|---|
| Price | $1.39 | $0.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $6.00 | $2.25 |
| AVG Volume (30 Days) | 65.1K | ★ 186.6M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $0.03 |
| 52 Week High | $2.73 | $2.79 |
Technical Indicators
Market Signals| Indicator | INAB | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 25.94 |
| Support Level | $1.35 | N/A |
| Resistance Level | $1.85 | $0.22 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 17.56 | 15.92 |
Price Performance
Historical ComparisonAbout INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.